Molecular epidemiology

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Pandemic, Tuberculosis, SAN, DNA, Organization, Disease, WHO, Risk, Genomics, Molecular epidemiology, Data analysis, Whole genome sequencing, Illumina, Inc., Drug resistance, Clinical epidemiology, SARS-COV-2, Virus, GISAID, AIDS, Communication, Moeder, SARS-CoV-2, Face, Public, Influenza-like illness, Vaccine, Renewable energy, Malaria, Developing country, Illumina

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs). The program, developed with guidance from customers, funders, and market facilitators including the nonprofit FIND, will provide reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities and address key international logistics and supply chain challenges.

Key Points: 
  • SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs).
  • "We know that enabling countries to perform pathogen sequencing locally strengthens health systems, enables better preparedness, and empowers countries to manage their priority health threats," said Vanessa Moeder, head of Global Health at Illumina.
  • In the Illumina global team's experience, Moeder says, the countries or regions whose public health preparedness would most benefit from genomics often lack the resources to sustainably implement it.
  • The equitable access program developed and operationalized by Illumina will allow many low- and middle-income nations to participate in the future of genomics across public health and preparedness."

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Retrieved on: 
Monday, October 9, 2023
Bureau of Oceans and International Environmental and Scientific Affairs, City of Hope National Medical Center, Mayo Clinic, Family, College, College of Physicians & Surgeons of Mumbai, Breast cancer, Medicine, PP2A, Cancer, Toxicity, Molecular epidemiology, Columbia University, City, AOA, NCI, Princeton University, Pharmacology, Patient, Surgeon, Pharmaceutical industry, Management

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D.
  • Dr. Kovach, 87, founded the Company in 2005 and held a distinguished medical and scientific career that focused on the causation and treatment of cancer.
  • Dr. Kovach served as LIXTE’s President and Chief Executive Officer from 2005 through September 26, 2023.
  • In connection with the Company’s management succession plan, Dr. Kovach was succeeded as President and Chief Executive Officer by Bas van der Baan on that date.

BioVaxys and The Ohio State University Extend Research Collaboration

Retrieved on: 
Wednesday, August 30, 2023
Vaccine, Infection, Ohio State University, Molecular epidemiology, Bachelor, Nextgen, CSE, University, Prevalence, Vaccination, Environmental science, SARS-CoV-2, Public, United States Department of Defense, COVID-19, Immunity, Mutation, Research, FRA, Doctor of Philosophy, Government, Animal science, COVID-19 vaccine, Animal, Risk, OTC, Viral, Privacy and the US government, Diagnosis, SAM, Ohio State University College of Medicine, Virus, NIH, World Health Organization, Pharmaceutical industry

VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.

Key Points: 
  • VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.
  • This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.
  • There are growing concerns about the recently emerging Covid-19 variant EG.5 ("EG.5").
  • The collaborating laboratory at The Ohio State University is led by virologist Professor Qiuhong Wang, Bachelor of Medicine (China) and PhD (USA), from the University's Center for Food Animal Health , Department of Animal Sciences, College of Food, Agricultural, & Environmental Sciences.

BioVaxys and The Ohio State University Extend Research Collaboration

Retrieved on: 
Wednesday, August 30, 2023
Vaccine, Infection, Ohio State University, Molecular epidemiology, Bachelor, Nextgen, CSE, University, Prevalence, Vaccination, Environmental science, SARS-CoV-2, Public, United States Department of Defense, COVID-19, Immunity, Mutation, Research, FRA, Doctor of Philosophy, Government, Animal science, COVID-19 vaccine, Animal, Risk, OTC, Viral, Privacy and the US government, Diagnosis, SAM, Ohio State University College of Medicine, Virus, NIH, World Health Organization, Pharmaceutical industry

VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.

Key Points: 
  • VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research collaboration with The Ohio State University ("The Ohio State") for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.
  • This is the second twelve-month extension of the research collaboration between BioVaxys and the University since 2021.
  • There are growing concerns about the recently emerging Covid-19 variant EG.5 ("EG.5").
  • The collaborating laboratory at The Ohio State University is led by virologist Professor Qiuhong Wang, Bachelor of Medicine (China) and PhD (USA), from the University's Center for Food Animal Health , Department of Animal Sciences, College of Food, Agricultural, & Environmental Sciences.

Genomics Market to Reach $94.86 Billion by 2030 at CAGR 16.5%: Grand View Research, Inc.

Retrieved on: 
Wednesday, April 19, 2023
Metagenomics, Survivor, CRISPR, Molecular epidemiology, Chromosome, Therapy, SARS-CoV-2, Genomics, National Centre for Disease Control, University of Cambridge, NGS, IHOP, National Cancer Institute, Pathway analysis, Inherited disorders of trafficking, Research, Genetic Alliance, Infection, OGL, DSM-IV codes, Biomarker, USD, Government, CDC, Whole genome sequencing, Revenue, Nature, SAN, Biomarker discovery, Functional genomics, Cancer, Merck & Co., Rare, Gene, Genetic disorder, Disease, Illumina, Inc., Antibiotics, Vaccine, Epigenomics

SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is expected to register a CAGR of 16.5% in the forecast period owing to the increasing demand for novel therapeutic and research applications in genomics.
  • Read full market research report more latest industry insights, " Genomics Market Size, Share & Trends Analysis Report By Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), By Deliverables, End-use, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global genomics market on the basis of application, deliverables, end-use, and region
    Genomics Market - Application & Technology Outlook (Revenue, USD Million, 2018 - 2030)

Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, April 13, 2023
Abstract (summary), Molecular epidemiology, AACR, Drug development, Bone sarcoma, Catholic higher education, Faculty of Theology, Catholic University of Leuven, University Hospitals Cleveland Medical Center, KU, American Association for Cancer Research, Soft-tissue sarcoma, STS, Sarcoma, Cancer, UZ Leuven, ADC, Poster, Receptor (biochemistry), Spacecraft, Laboratory, Tumor microenvironment, Cooper University Hospital, Medical imaging, KU Leuven

Based on its differentiated expression profile, uPARAP is an attractive novel target for development of uPARAP-targeting ADCs in a broad range of sarcoma subtypes.

Key Points: 
  • Based on its differentiated expression profile, uPARAP is an attractive novel target for development of uPARAP-targeting ADCs in a broad range of sarcoma subtypes.
  • Additionally, uPARAP receptor levels may serve as a potential biomarker for patient enrichment in clinical studies of such uPARAP-targeting ADCs.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, said: "We are excited to share data on the expression of uPARAP in soft tissue and bone sarcoma.
  • In addition to its differentiated expression profile in multiple sarcoma subtypes uPARAP is a constitutively recycling endocytic receptor with unique internalization properties, making it a highly attractive ADC target."

Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, April 13, 2023
Abstract (summary), Molecular epidemiology, AACR, Drug development, Bone sarcoma, Catholic higher education, Faculty of Theology, Catholic University of Leuven, University Hospitals Cleveland Medical Center, KU, American Association for Cancer Research, Soft-tissue sarcoma, STS, Sarcoma, Cancer, UZ Leuven, ADC, Poster, Receptor (biochemistry), Spacecraft, Laboratory, Tumor microenvironment, Cooper University Hospital, Medical imaging, KU Leuven

Based on its differentiated expression profile, uPARAP is an attractive novel target for development of uPARAP-targeting ADCs in a broad range of sarcoma subtypes.

Key Points: 
  • Based on its differentiated expression profile, uPARAP is an attractive novel target for development of uPARAP-targeting ADCs in a broad range of sarcoma subtypes.
  • Additionally, uPARAP receptor levels may serve as a potential biomarker for patient enrichment in clinical studies of such uPARAP-targeting ADCs.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, said: "We are excited to share data on the expression of uPARAP in soft tissue and bone sarcoma.
  • In addition to its differentiated expression profile in multiple sarcoma subtypes uPARAP is a constitutively recycling endocytic receptor with unique internalization properties, making it a highly attractive ADC target."

Flagship Biosciences appoints Gina Wallar, Ph.D., MPH as new Chief Commercial Officer

Retrieved on: 
Thursday, March 9, 2023
Science, Boston University, Research, CCO, MPH, Risk, UCLA, Cancer, Norwich Pharma Services, Disease, Bureau of Oceans and International Environmental and Scientific Affairs, Molecular epidemiology, PD-L1, Doctor of Philosophy, Senior, Genetics, Management, Flagship, Biostatistics

BROOMFIELD, Colo., March 9, 2023 /PRNewswire-PRWeb/ -- Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the appointment of Gina Wallar, Ph.D., MPH as their new Chief Commercial Officer. Gina is an accomplished business executive in the diagnostics and pharma services industry with 20 years' experience leading international sales teams, managing people, and spearheading business development from a financial perspective.

Key Points: 
  • , a leader in spatial biology and biomarker analytics services, announced the appointment of Gina Wallar, Ph.D. , MPH as their new Chief Commercial Officer.
  • Gina brings over 20 years of experience in commercial, operational, and scientific expertise, having held leadership positions at several large, commercial organizations," said CEO Trevor Johnson.
  • Prior to joining Flagship Biosciences, Dr. Wallar acted as Senior Vice President for Fulgent Genetics where she led their sales and business development efforts.
  • "This is a remarkable time to join the Flagship Biosciences team," said Gina.

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Retrieved on: 
Tuesday, January 17, 2023
Associate, Roche, Center for Epidemiologic Studies Depression Scale, MS, Genetic counseling, Molecular epidemiology, Pancreatic cancer, Medical Affairs Bureau, Economics, Ohio State University, Diagnosis, Survival, Genomics, Engineering, Roche Diagnostics, Cancer, Doctor of Philosophy, Pharmaceutical industry, Genetics, Genetic

Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.

Key Points: 
  • Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.
  • Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University.
  • Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis.
  • Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications.

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Retrieved on: 
Tuesday, January 17, 2023
Associate, Roche, Center for Epidemiologic Studies Depression Scale, MS, Genetic counseling, Molecular epidemiology, Pancreatic cancer, Medical Affairs Bureau, Economics, Ohio State University, Diagnosis, Survival, Genomics, Engineering, Roche Diagnostics, Cancer, Doctor of Philosophy, Pharmaceutical industry, Genetics, Genetic

Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.

Key Points: 
  • Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.
  • Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University.
  • Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis.
  • Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications.